Abiraterone Description

Abiraterone is a acquired of steroidal progesterone and is an avant-garde biologic that offers analytic account to patients with hormone adverse prostate cancer. Abiraterone is administered as an acetate alkali prodrug because it has a college bioavailability and beneath affected to hydrolysis than abiraterone itself. FDA accustomed on April 28, 2011.

Abiraterone is associated with decreases in PSA levels, bump abbreviating (as evaluated by RECIST criteria), radiographic corruption of cartilage metastases and advance in pain. Levels of adrenocorticotropic hormones added up to 6-fold but this can be suppressed by dexamethasone.

Abiraterone is an orally alive inhibitor of the steroidal agitator CYP17A1 (17 alpha-hydroxylase/C17,20 lyase). It inhibits CYP17A1 in a careful and irreversible address via covalent bounden mechanism. CYP17A1 is an agitator that catalyzes the biosynthesis of androgen and is awful bidding in testicular, adrenal, and prostatic bump tissue. More specifically, abiraterone inhibits the about-face of 17-hydroxyprognenolone to dehydroepiandrosterone (DHEA) by the agitator CYP17A1 to abatement serum levels of testosterone and added androgens.